Anne Li 6/17/17 For more information please email: firstname.lastname@example.org
For nearly two decades researchers have sought a way to target an estrogen receptor in the hope they could improve breast cancer survival, but an article published in Nature Communications contends that the effort may never pan out. The reason? The target receptor does not actually appear to be where they believe it to be. The study questions whether reliance on insufficiently-validated antibodies has led science down a dead-end path since the discovery of estrogen receptor beta (ESR2) in the 1990s. Cecilia Williams, a researcher at KTH Royal Institute of Technology in Stockholm and the joint research center, Science for Life Laboratory (SciLifeLab), says the beta receptor's discovery changed our understanding of estrogen signaling. It also raised hopes for a new endocrine treatment to complement the success of estrogen-blocking drugs such as Tamoxifen.
See original article at: https://www.sciencedaily.com/releases/2017/06/170615084748.htm